Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 3 selected

Guidance programme

Showing 1 to 50 of 106

TitleReference numberPublishedLast updated
Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and overHST33
Burosumab for treating X-linked hypophosphataemia in children and young peopleHST8
Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type BHST32
Tobacco: preventing uptake, promoting quitting and treating dependenceNG209
Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 yearsNG247
Urinary tract infection (recurrent): antimicrobial prescribingNG112
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Sebelipase alfa for treating Wolman diseaseHST30
Velmanase alfa for treating alpha-mannosidosisHST29
Birch bark extract for treating epidermolysis bullosaHST28
Afamelanotide for treating erythropoietic protoporphyriaHST27
Lumasiran for treating primary hyperoxaluria type 1HST25
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiencyHST26
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Setmelanotide for treating obesity caused by LEPR or POMC deficiencyHST21
Social, emotional and mental wellbeing in primary and secondary educationNG223
Reducing sexually transmitted infectionsNG221
Vaccine uptake in the general populationNG218
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and overHST20
Elosulfase alfa for treating mucopolysaccharidosis type 4AHST19
Atidarsagene autotemcel for treating metachromatic leukodystrophyHST18
Integrated health and social care for people experiencing homelessnessNG214
Otitis media (acute): antimicrobial prescribingNG91
Mental wellbeing at workNG212
Odevixibat for treating progressive familial intrahepatic cholestasisHST17
Givosiran for treating acute hepatic porphyriaHST16
Looked-after children and young peopleNG205
Clostridioides difficile infection: antimicrobial prescribingNG199
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribingNG190
Metreleptin for treating lipodystrophyHST14
Human and animal bites: antimicrobial prescribingNG184
Volanesorsen for treating familial chylomicronaemia syndromeHST13
Behaviour change: digital and mobile health interventionsNG183
Insect bites and stings: antimicrobial prescribingNG182
Impetigo: antimicrobial prescribingNG153
Leg ulcer infection: antimicrobial prescribingNG152
Indoor air quality at homeNG149
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2HST12
Workplace health: long-term sickness absence and capability to workNG146
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutationsHST11
Cellulitis and erysipelas: antimicrobial prescribingNG141
Pneumonia (community-acquired): antimicrobial prescribingNG138
Pneumonia (hospital-acquired): antimicrobial prescribingNG139
Patisiran for treating hereditary transthyretin amyloidosisHST10
Alcohol interventions in secondary and further educationNG135
Inotersen for treating hereditary transthyretin amyloidosisHST9
Cough (acute): antimicrobial prescribingNG120

Results per page

  1. 10
  2. 25
  3. 50
  4. All